Advancing iPSC-derived NK cell therapyPublished: December 19, 2019
2020 vision - Tools and Technologies of Tomorrow
Bahram (Bob) Valamehr is the Chief Development Officer at Fate Therapeutics, overseeing the company’s early development activities including ‘off-the-shelf’ cell therapy product candidates derived from the company’s induced pluripotent stem cell platform. Previously, Dr Valamehr was the Vice President of Cancer Immunotherapy at Fate and prior to that played ey scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr Valamehr received his PhD from the Department of Molecular and Medical Pharmacology at UCLA, his MBA from Pepperdine University and his BS from the Department of Chemistry and Biochemistry at UCLA.DOI: 10.18609/cgti.2019.173
Citation: Cell & Gene Therapy Insights 2019; 5(12), 1655-1661.